A Study to Investigate the Safety and Tolerability of Intravenous QEQ278 in Patients With Advanced Solid Tumors

NCT ID: NCT05462873

Last Updated: 2025-08-26

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2023-04-04
• Study Completion Date: 2026-01-20

Brief Summary

To characterize safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of QEQ278 in adult patients with advanced/metastatic non-small cell lung cancer, esophageal squamous cell carcinoma, renal cell carcinoma, and human papilloma virus associated head and neck squamous cell carcinoma.

Detailed Description

This study is an open-label, phase I/Ib, multi-center study of QEQ278 as a single agent, consisting of a dose escalation part followed by a dose expansion part.

In the dose escalation part of the study, patients with non-small cell lung cancer (NSCLC), esophageal squamous cell carcinoma (ESCC), renal cell carcinoma (RCC), or human papilloma virus (HPV)-associated head and neck squamous cell carcinoma (HNSCC) will be treated with QEQ278 single agent until the maximum tolerated dose (MTD) is reached or a lower recommended dose (RD) is established.

The study may enter the dose expansion, after an MTD(s) and/or RD(s) is declared in the dose escalation.

Conditions

Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Esophageal Squamous Cell Carcinoma; Squamous Cell Carcinoma of Head and Neck

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Part 1: Dose escalation

Dose escalation with QEQ278 single agent

Group Type: EXPERIMENTAL

QEQ278

Intervention Type: BIOLOGICAL

Intravenous dosing of QEQ278

Part 2: Dose expansion

Dose expansion with QEQ278 single agent

Group Type: EXPERIMENTAL

QEQ278

Intervention Type: BIOLOGICAL

Intravenous dosing of QEQ278

Interventions

QEQ278

Intravenous dosing of QEQ278

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• Signed informed consent must be obtained prior to participation in the study.
• Adult men and women ≥ 18 years of age.
• Histologically confirmed and documented advanced malignancies (locally advanced malignancies, non-curable by surgery or radiotherapy and metastatic disease). Disease must be measurable, including presence of at least one measurable lesion, as determined by RECIST v1.1.
• In the opinion of the treating investigator, patients must have received, but are not benefitting from standard therapies, be intolerant or ineligible to receive such therapy, or have no standard therapy option for the respective disease types (diseases listed below), as well as any other therapies deemed to be standard by local/institutional standard.
• Non-small cell lung cancer
• Esophageal squamous cell carcinoma
• Renal cell carcinoma
• HPV-associated head and neck squamous cell carcinoma
• Must have a site of disease amenable to biopsy and be a candidate for tumor biopsy according to the treating institution's guidelines. The patient must be willing to undergo a new tumor biopsy at screening and during treatment.

Exclusion Criteria

• Active previously documented or suspected autoimmune disease. Patients with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone replacement, psoriasis not requiring systemic treatment, or conditions not expected to recur should not be excluded. Patients previously exposed to anti-PD-1/PD-L1 treatment who are adequately treated for skin rash or with replacement therapy for endocrinopathies should not be excluded.
• Patients with a history of or current interstitial lung disease or pneumonitis ≥ Grade 2.
• Patients who discontinued prior anti-PD-1 therapy due to an anti-PD-1-related toxicity
• Clinically significant cardiac disease or risk factors at screening
• Insufficient bone marrow function at screening:
• Infections:
• Known history of testing positive for Human Immunodeficiency Virus infection.
• Active Hepatitis B and / or Hepatitis C.
• Active, documented COVID-19 infection
• Known history of tuberculosis
• Any serious uncontrolled infection (acute or chronic).
• Systemic chronic steroid therapy (>10 mg/day prednisone or equivalent) or any immunosuppressive therapy, other than replacement-dose steroids in the setting of adrenal insufficiency, within 7 days of the first dose of study treatment. Topical, inhaled, and ophthalmic steroids are allowed.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Novartis Pharmaceuticals

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

University of California LA

Los Angeles, California, United States

Florida Cancer Specialists

Fort Myers, Florida, United States

Massachusetts General Hospital Dept. of Mass General Hospital

Boston, Massachusetts, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Novartis Investigative Site

Brussels, , Belgium

Novartis Investigative Site

Paris, , France

Novartis Investigative Site

Essen, , Germany

Novartis Investigative Site

Milan, MI, Italy

Novartis Investigative Site

Kashiwa, Chiba, Japan

Novartis Investigative Site

Singapore, , Singapore

Novartis Investigative Site

Barcelona, Catalonia, Spain

Novartis Investigative Site

Taipei, , Taiwan

Countries

United States; Belgium; France; Germany; Italy; Japan; Singapore; Spain; Taiwan

Other Identifiers

CQEQ278A12101

Identifier Type: -

Identifier Source: org_study_id